| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2971071 | The Journal of Heart and Lung Transplantation | 2010 | 8 Pages |
Abstract
The development of DSA is surprisingly common after lung transplantation. Antibody-directed therapy may reduce the risk of rejection associated with DSA, but a randomized controlled trial is necessary to critically evaluate the efficacy of this treatment protocol.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Ramsey R. MD, Roger D. MD, Bryan F. MD, Aviva A. RN, Thalachallour PhD, G. Alexander MD, Elbert P. MD,